Article

Microplasmin receives orphan drug protection

Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Related Content
Opus Genetics reports 1-month pediatric results in gene therapy for inherited retinal disease
April 8th 2025

Opus Genetics reports 1-month pediatric results in gene therapy for inherited retinal disease

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Myopia onset predicted by accelerated eye changes a year in advance
April 2nd 2025

Myopia onset predicted by accelerated eye changes a year in advance

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

ARVO announces Swathi Kaliki, MD, as recipient of 2025 Ludwig von Sallmann Clinician-Scientist Award
March 15th 2025

ARVO announces Swathi Kaliki, MD, as recipient of 2025 Ludwig von Sallmann Clinician-Scientist Award

FDA accepts new drug application for low-dose atropine from Sydnexis
March 11th 2025

FDA accepts new drug application for low-dose atropine from Sydnexis

© 2025 MJH Life Sciences

All rights reserved.